Jordan Rubenstein,Sarah M Schwartz,Jay Vankawala et al.
Jordan Rubenstein et al.
Imatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), is associated with myalgia and creatine kinase (CK) elevations, though severe rhabdomyolysis and myopathy are rare. We...
Pediatric AML in Sousse, Tunisia: Epidemiologic patterns and hierarchical prognostic factors [0.03%]
突尼斯苏塞儿童急性髓系白血病的流行特征及分级预后因素分析
Donia Bouhoula,Haifa Regaieg,Hela Abroug et al.
Donia Bouhoula et al.
Pediatric acute myeloid leukemia outcomes in resource-limited regions remain understudied, particularly regarding how regional epidemiologic patterns interact with prognostic determinants. Our Tunisian cohort (n=68) reveals distinct pediatr...
Long-term outcomes of pediatric AML in Tunisia: Lessons from 19 years of practice in Sousse [0.03%]
突尼斯儿童急性髓系白血病的长期结局——苏塞19年实践经验总结
Donia Bouhoula,Haifa Regaieg,Hela Abroug et al.
Donia Bouhoula et al.
Treating pediatric acute myeloid leukemia in resource-limited settings presents unique therapeutic challenges. This study shares 19 years of experience from a Tunisian center, focusing on practical treatment outcomes. Our pediatric AML coho...
BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d'Ivoire [0.03%]
BCR-ABL1酪氨酸激酶域突变及其对科特迪瓦低收入国家慢性髓系白血病患者伊马替尼一线治疗结局预测价值的经验研究
Kouassi Gustave Koffi,Sara Akou Bognini,Dohoma Alexis Silué et al.
Kouassi Gustave Koffi et al.
Background: We aimed to analyse the incidence of BCR::ABL1 kinase domain mutations in patients newly diagnosed with or undergoing treatment for chronic myeloid leukemia (CML) in Côte d'Ivoire, as well as to evaluate the ...
Corrigendum to "Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification" [Leukemia Research Reports 24 (2025) 100550] [0.03%]
关于“通过新型风险分层揭开接受低甲基化剂和维奈克拉治疗的急性髓系白血病患者预后”一文的勘误（《白血病研究报告》24卷(2025) 100550号论文）
Jiajia Sun,Zhiping Guo
Jiajia Sun
[This corrects the article DOI: 10.1016/j.lrr.2025.100550.]. © 2025 The Authors.
Published Erratum
Leukemia research reports. 2025 Oct 30:24:100551. DOI:10.1016/j.lrr.2025.100551 2025
Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An indian experience [0.03%]
利妥昔单抗维持治疗对印度FL患者预后影响的研究
Harish Pant,Ajay Gogia,Atul Sharma et al.
Harish Pant et al.
Background: Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) and comprises 9 % of total NHL in India. Rituximab maintenance (RM) after induction immunochemotherapy improves PFS. How...
A rare case of variant acute promyelocytic leukemia with FIP1L1-RARA fusion gene: case report and literature review [0.03%]
FIP1L1-RARA融合基因变异急性早幼粒细胞白血病一例及相关文献复习
Yanyan Qiu,Huarong Zhou,Shaoyuan Wang
Yanyan Qiu
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by the promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) fusion gene and exceptional responsiveness to differentiation therapy wit...
Extramedullary breast infiltration as the initial manifestation of adult acute B-lymphoblastic leukemia with TCF3::PBX1 fusion gene recurrence and adenofibroma: A case report [0.03%]
TCF3::PBX1融合基因复发伴腺纤维瘤的成人急性B淋巴细胞白血病髓外乳腺浸润一例报告
Liya Liu,Ying Yu,Xueyan Chen
Liya Liu
Extramedullary breast relapse of leukemia is uncommon and primarily occurs in cases of acute myeloid leukemia(AML), and secondary acute lymphoblastic leukemia (ALL) affecting the breast may also occur occasionally. The mechanism of extramed...
Pediatric chronic myeloid leukemia: A decade of clinical experience at the NBK specialized hospital for children [0.03%]
儿童慢性粒细胞白血病的临床经验——NBK儿童专科医院十年案例分析
Maha Bourusly,Mohammad Adil Obaid,Nashwa Farag et al.
Maha Bourusly et al.
Pediatric chronic myeloid leukemia is rare and differs from adult disease. We retrospectively reviewed 12 children (median age 8.4 years, six males) treated with imatinib (340 mg/m²/day) from 2010 to 2020; dasatinib was used for intoleranc...
Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification [0.03%]
通过新型风险分层揭示接受低甲基化药物和维奈克拉治疗的急性髓系白血病患者预后
Jiajia Sun,Zhiping Guo
Jiajia Sun
Several genetic risk classification systems based on response to older acute myeloid leukemia patients treated with less-intensive regimens, especially venetoclax (VEN) + hypomethylating agent (HMA), are proposed recently. VEN+HMA improved ...